TBScience is an official event entirely devoted to basic and translational tuberculosis research, held between 19-22 October 2021 as part of The Union World Conference. TBScience abstract submissions are open until Tuesday, 20 July 2021 (23:59 CEST).
Community Connect is an area where representatives from the community can share, experience and develop ideas and projects around 4 tracks related to lung health and non-communicable diseases. Community Connect session submissions are open until Friday, 28 June 2021 (23:59 CEST).
If you would like a unique opportunity to present your research or programme work, Satellite Sessions will continue to remain open till Wednesday, 30 June 2021 (23:59 CEST). Abstract and Session submissions are, however, closed.
Submissions for late-breaker sessions will open from 15 July to 12 August. More details will become available by the end of this month.
-Registration for the conference will open in August. For any further questions, please contact
- TBScience submissions are now open. Submissions will close on 20 July, 2021 (23:59 CEST).
- Community Connect submissions are now open. Submissions will close on 28 June, 2021 (23:59 CEST).
- Satellite submissions to remain open till June 30, 2021 (23:59 CEST).
- Registration for the Conference will begin in August.
This year abstract submissions, either oral or poster presentations, should be aligned with one of these four session themes:
Theme 1: Tools to guide personalised therapy – what is achievable?
The treatment of tuberculosis utilises multiple antibiotics given for many weeks or months. In order to ensure reproducible treatment success everyone must take the full course of antibiotics. Treatment shortening equivalence trials have shown that the majority of people have achieved relapse free cure before the end of standard TB therapy. A test able to monitor the disease course and predict cure could provide an opportunity to make personalised treatment decisions including decisions on treatment shortening. This session will discuss the feasibility of this goal, recent advances and insights, and the potential contribution of biomarkers to monitor response and dynamically individualise therapy.
Theme 2: Recent innovations in trial design, lessons for the TB community. Where does TB treatment innovation go from here?
Platform trials set up in response to COVID-19 have yielded remarkable success. This session aims to explore how the TB community can learn from these innovations in trial design and build upon the recent success in generating the evidence base for shortening treatment regimens. It will cover innovations in trial designs and reflect on their contribution to further accelerate TB treatment development.
Theme 3: Bioaerosols: Threats and opportunities
The COVID-19 pandemic has refocused attention on how infectious diseases transmit from person to person, and has catalysed innovations in sampling and diagnostics. This session aims to explore how pathogen bioaerosols arise, persist in different environments, and infect other hosts, and how the innovations and knowledge gained from the COVID-19 response can be harnessed to improve TB infection prevention and control, and TB diagnosis.
Theme 4: TB vaccines: Aspiring is not enough!
The speed of the development of COVID-19 vaccines is in stark contrast to the speed of TB vaccine development. Can the investment in COVID-19 vaccine development support TB vaccine development, including accelerating development of the most advanced new TB vaccine candidates and of mRNA-based TB vaccines? This session will review the recent advances in vaccine research and address advances and gaps in understanding protective immunity critical for vaccine discovery.
TBScience is devoted to basic and clinical science on tuberculosis. Abstracts should:
- Respond to at least one of the 4 session themes
- Contain original data not published at the time of the abstract submission deadline
- Focus on any of the following research fields:
– Basic research (microbiology, immunology, -omics, etc)
– Animal model studies
– Clinical research
– Epidemiology and transmission modeling
- Not eligible are abstracts related to:
– Implementation, operational and programmatic research
– Descriptive epidemiology (e.g. prevalence surveys)
– Health economics, social science research